Molecular biology of PCSK9: its role in LDL metabolism.

Jay D Horton, Jonathan C Cohen, Helen H Hobbs

Journal: Trends in biochemical sciences 2007;32(2):71-7

PMID: 17215125

Free Full Text on PubMed Central View on PubMed

Abstract

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in liver and thereby controls the level of LDL in plasma. Mutations that increase PCSK9 activity cause hypercholesterolemia and coronary heart disease (CHD); mutations that inactivate PCSK9 have the opposite effect, lowering LDL levels and reducing CHD. Although the mechanism of PCSK9 action is not yet clear, the protease provides a new therapeutic target to lower plasma levels of LDL and prevent CHD.

Address: Departments of Internal Medicine and Molecular Genetics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9046, USA. [email protected]

DOI: 10.1016/j.tibs.2006.12.008

Link outs

Free resources

Full Text Sources:

Medical:

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3369

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0968...

MeSH Terms: Cholesterol, LDL, Coronary Disease, Genetic Variation, Humans, Hypolipoproteinemias, Molecular Biology, Proprotein Convertase 9, Proprotein Convertases, Serine Endopeptidases